Abstract
Limited insulin pump cartridge volumes can present challenges to automated insulin delivery (AID) system use for adolescents and young adults (AYA) with type 1 diabetes (T1D) and high insulin requirements. We assessed the real-world safety and effectiveness of U200 concentrated insulin use in AID (U200-AID) among AYAs with T1D. We conducted a two-center, retrospective cohort study assessing glycemia, pump utilization, and safety outcomes pre-/post-U200-AID. Among 50 AYAs initiating U200-AID (age 15.4 years, T1D duration 5.5 years, hemoglobin A1c 8.5%), time in range (70–180 mg/dL) increased (44.6% ± 12.6% vs. 48.9% ± 11.4%, P = 0.012) and time below range (<70 mg/dL) did not change significantly. Days between cartridge changes increased (2.2 ± 0.5 vs. 3.0 ± 0.5 days, P < 0.001) despite increased total daily insulin dose (102.6 ± 23.5 vs. 125.8 ± 38.9 U100 insulin units, P < 0.001). No severe hypoglycemia or diabetic ketoacidosis occurred (median follow-up 290 days [interquartile range 227, 476]). These data suggest that U200-AID is a viable option for individuals with T1D and high insulin requirements.
Keywords
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
